You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 16, 2025

CLINICAL TRIALS PROFILE FOR NAMENDA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Namenda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed Fisher Center for Alzheimer's Research Foundation Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed Forest Laboratories Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed New York University School of Medicine Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗ Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training Completed NYU Langone Health Phase 4 2006-08-01 The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Namenda

Condition Name

Condition Name for Namenda
Intervention Trials
Alzheimer's Disease 6
Autism Spectrum Disorder 4
Autism 4
Traumatic Brain Injury 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Namenda
Intervention Trials
Disease 13
Cognitive Dysfunction 10
Alzheimer Disease 8
Autistic Disorder 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Namenda

Trials by Country

Trials by Country for Namenda
Location Trials
United States 244
Canada 5
Spain 4
Korea, Republic of 4
Colombia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Namenda
Location Trials
California 18
Massachusetts 17
New York 16
Illinois 10
Maryland 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Namenda

Clinical Trial Phase

Clinical Trial Phase for Namenda
Clinical Trial Phase Trials
Phase 4 22
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Namenda
Clinical Trial Phase Trials
Completed 50
Recruiting 6
Terminated 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Namenda

Sponsor Name

Sponsor Name for Namenda
Sponsor Trials
Forest Laboratories 28
Massachusetts General Hospital 10
National Cancer Institute (NCI) 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Namenda
Sponsor Trials
Other 98
Industry 31
NIH 13
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Namenda and Its Place in Alzheimer's Disease Treatment: Clinical Trials, Market Analysis, and Projections

Introduction to Namenda

Namenda, also known as memantine, is a medication widely used in the treatment of moderate to severe Alzheimer's disease. It is often prescribed in combination with other drugs, such as donepezil, under the brand name Namzaric.

Clinical Trials and Current Usage

Namenda in Combination Therapies

Namenda is frequently used in combination with other Alzheimer's medications. For example, the combination drug Namzaric, which includes both memantine and donepezil, has been a common treatment approach. Clinical trials have focused on the efficacy and safety of these combination therapies rather than Namenda alone in recent years[2].

Ongoing and Completed Trials

While there are no major new clinical trials specifically focused on Namenda as a standalone treatment, ongoing research often includes memantine as part of combination therapies. For instance, a randomized, double-blind clinical trial is underway to determine whether memantine enhances targeted cognitive training (TCT) learning. This trial, sponsored by the University of California, San Diego, aims to assess the augmentation of TCT by memantine[4].

Market Analysis

Current Market Position

Namenda, particularly in its combination form as Namzaric, has been a significant player in the Alzheimer's disease market. However, its sales are expected to be impacted by the impending availability of generic versions. The exclusive commercialization rights for Namzaric in the US are held by Allergan, while Adamas Pharmaceuticals retains rights outside the US[5].

Market Forecast

The Alzheimer's disease market is projected to grow significantly, driven by the increasing prevalence of the disease and the introduction of new therapies. By 2026, the global Alzheimer's disease market is expected to reach $14.8 billion, growing at a Compound Annual Growth Rate (CAGR) of 17.5%[2].

Impact of Generic Versions

A critical factor affecting Namenda's market position is the upcoming availability of generic versions. Allergan has reached a deal with Amneal Pharmaceuticals, allowing Amneal to market generic versions of Namzaric starting from January 1, 2025, pending FDA approval. This will likely lead to a decline in Namzaric's sales as generic alternatives become available[5].

Projections and Future Outlook

Sales Projections

Namzaric's sales have been steadily increasing since its launch in 2016, but they are expected to peak at $574.1 million in 2025 before declining as generic versions enter the market. Despite this, the overall Alzheimer's disease market is expected to continue growing, driven by new disease-modifying therapies and increasing public awareness[2].

Competitive Landscape

The Alzheimer's disease market is highly competitive, with several new drug classes and therapies in the pipeline. Monoclonal antibody-based immunotherapies and BACE inhibitors are expected to be major contributors to market growth. The launch of aducanumab, an amyloid-beta targeting immunotherapy, is a key example of this trend, with projected sales of $3 billion by 2026[2].

Key Takeaways

  • Clinical Trials: While Namenda is not the focus of new standalone clinical trials, it remains part of combination therapies in ongoing research.
  • Market Position: Namenda, especially in its combination form as Namzaric, is a significant player but faces competition from upcoming generic versions.
  • Market Forecast: The Alzheimer's disease market is expected to grow significantly, but Namzaric's sales will likely decline with the introduction of generics.
  • Future Outlook: The market will be driven by new disease-modifying therapies, with a focus on early-stage treatments and combination therapies.

FAQs

What is Namenda used for?

Namenda, or memantine, is used to treat moderate to severe Alzheimer's disease. It is often prescribed in combination with other medications.

When will generic versions of Namzaric be available?

Generic versions of Namzaric are expected to be available starting from January 1, 2025, pending FDA approval.

How will the availability of generic versions affect Namzaric's sales?

The availability of generic versions is expected to lead to a decline in Namzaric's sales as patients and healthcare providers opt for the more affordable generic alternatives.

What are the projected sales for Namzaric by 2025?

Namzaric's sales are expected to peak at $574.1 million in 2025 before declining with the introduction of generic versions.

What are some of the new therapies expected to impact the Alzheimer's disease market?

New therapies include monoclonal antibody-based immunotherapies, such as aducanumab, and BACE inhibitors, which are expected to significantly contribute to market growth.

Sources

  1. Alzheimer's Society - Three promising drugs for treating Alzheimer's disease bring fresh hope
  2. Drug Development Technology - MARKET BRIEF - Alzheimer's Disease Market Report (2016-2026)
  3. Exploration Pub - Current therapeutics for Alzheimer's disease and clinical trials
  4. ClinicalTrials.gov - Memantine Augmentation of Targeted Cognitive Training in Alzheimer's Disease
  5. GaBI Online - Allergan allows Amneal to market Alzheimer's generic in 2025

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.